Militia Capital Partners LP Has $1.66 Million Stock Position in Eli Lilly and Company $LLY

Militia Capital Partners LP decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 40.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,540 shares of the company’s stock after selling 1,060 shares during the period. Militia Capital Partners LP’s holdings in Eli Lilly and Company were worth $1,655,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its position in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. lifted its position in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Finally, Miller Global Investments LLC acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,122.47 on Wednesday. The business has a 50 day simple moving average of $1,006.08 and a 200 day simple moving average of $1,016.63. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market cap of $1.06 trillion, a price-to-earnings ratio of 39.87, a PEG ratio of 1.23 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the business earned $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
• Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
• Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
• Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
• Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
• Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Finally, Berenberg Bank upped their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.